Evidence map›Paper›PMID 38698395›Full record

ArticleBMC medical informatics and decision making2024

Exploring machine learning strategies for predicting cardiovascular disease risk factors from multi-omic data.

Gabin Drouard, Juha Mykkänen, Jarkko Heiskanen, Joona Pohjonen, Saku Ruohonen, Katja Pahkala, Terho Lehtimäki, Xiaoling Wang, Miina Ollikainen, Samuli Ripatti and 3 more

Abstract read
In one paragraph

Article in BMC medical informatics and decision making, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Review
  2. Article
  3. Artificial intelligence to investigate metabolomics data for precision medicine.Metabolomics : Official journal of the Metabolomic Society · 2026
    Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Identification of novel hypertension biomarkers using explainable AI and metabolomics.Metabolomics : Official journal of the Metabolomic Society · 2024
    Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Gabin DrouardInstitute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland. gabin.drouard@helsinki.fi.
Juha MykkänenCentre for Population Health Research, University of Turku and Turku University Hospital, Turku, Finland.
Jarkko HeiskanenCentre for Population Health Research, University of Turku and Turku University Hospital, Turku, Finland.
Joona PohjonenResearch Program in Systems Oncology, University of Helsinki, Helsinki, Finland.
Saku RuohonenResearch Centre of Applied and Preventive Cardiovascular Medicine, University of Turku, Turku, Finland.
Katja PahkalaCentre for Population Health Research, University of Turku and Turku University Hospital, Turku, Finland.
Terho LehtimäkiDepartment of Clinical Chemistry, Fimlab Laboratories, and Finnish Cardiovascular Research Center - Tampere, Faculty of Medicine and Health Technology, Tampere University, 33520, Tampere, Finland.
Xiaoling WangGeorgia Prevention Institute, Medical College of Georgia, Augusta University, Augusta, GA, USA.
Miina OllikainenInstitute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland.
Samuli RipattiInstitute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland.
Matti PirinenInstitute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland.
Olli RaitakariCentre for Population Health Research, University of Turku and Turku University Hospital, Turku, Finland.
Jaakko KaprioInstitute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland. jaakko.kaprio@helsinki.fi.

Funding

A GENOME-WIDE METHYLATION STUDY ON ESSENTIAL HYPERTENSIONR01HL104125 · NHLBI · AUGUSTA UNIVERSITY · PI WANG, XIAOLING · 2011 to 2015
$2.9M
NHLBI NIH HHS R01 HL104125
6 · The paper itself

Abstract

backgroundMachine learning (ML) classifiers are increasingly used for predicting cardiovascular disease (CVD) and related risk factors using omics data, although these outcomes often exhibit categorical nature and class imbalances. However, little is known about which ML classifier, omics data, or upstream dimension reduction strategy has the strongest influence on prediction quality in such settings. Our study aimed to illustrate and compare different machine learning strategies to predict CVD risk factors under different scenarios.

methodsWe compared the use of six ML classifiers in predicting CVD risk factors using blood-derived metabolomics, epigenetics and transcriptomics data. Upstream omic dimension reduction was performed using either unsupervised or semi-supervised autoencoders, whose downstream ML classifier performance we compared. CVD risk factors included systolic and diastolic blood pressure measurements and ultrasound-based biomarkers of left ventricular diastolic dysfunction (LVDD; E/e' ratio, E/A ratio, LAVI) collected from 1,249 Finnish participants, of which 80% were used for model fitting. We predicted individuals with low, high or average levels of CVD risk factors, the latter class being the most common. We constructed multi-omic predictions using a meta-learner that weighted single-omic predictions. Model performance comparisons were based on the F1 score. Finally, we investigated whether learned omic representations from pre-trained semi-supervised autoencoders could improve outcome prediction in an external cohort using transfer learning.

resultsDepending on the ML classifier or omic used, the quality of single-omic predictions varied. Multi-omics predictions outperformed single-omics predictions in most cases, particularly in the prediction of individuals with high or low CVD risk factor levels. Semi-supervised autoencoders improved downstream predictions compared to the use of unsupervised autoencoders. In addition, median gains in Area Under the Curve by transfer learning compared to modelling from scratch ranged from 0.09 to 0.14 and 0.07 to 0.11 units for transcriptomic and metabolomic data, respectively.

conclusionsBy illustrating the use of different machine learning strategies in different scenarios, our study provides a platform for researchers to evaluate how the choice of omics, ML classifiers, and dimension reduction can influence the quality of CVD risk factor predictions.

Indexed as

Cardiovascular DiseasesMachine LearningAdultAgedFemaleFinlandHeart Disease Risk FactorsHumansMaleMetabolomicsMiddle AgedMultiomicsRisk AssessmentRisk FactorsAutoencodersBlood pressureCardiovascular diseaseDiastolic functionHypertensionImbalanced designMeta-learnersMulti-omicsPredictions

Identifiers

PMID38698395
PMCPMC11064347

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.